Bausch Health Reports Q4 2025 Earnings Miss
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 18 2026
0mins
Should l Buy BHC?
Source: seekingalpha
- Earnings Miss: Bausch Health's Q4 2025 financial results revealed a GAAP EPS of -$0.30, significantly below the expected $0.42, causing a ~4% drop in after-hours trading.
- Revenue Growth vs. Rising Expenses: The company reported revenue of approximately $2.8 billion, a 9.5% year-over-year increase that beat the consensus of $2.71 billion; however, a 16% YoY increase in expenses to ~$2.3 billion negatively impacted profitability.
- Positive Revenue Guidance: Bausch provided a 2026 revenue guidance of $10.625 billion to $10.875 billion, exceeding the consensus estimate of $10.52 billion, indicating confidence in future growth prospects.
- Improved Cash Position: By the end of 2025, Bausch's cash, cash equivalents, and restricted cash totaled $1.325 billion, up from $1.2 billion on December 31, 2024, reflecting better liquidity management.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BHC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BHC
Wall Street analysts forecast BHC stock price to rise
4 Analyst Rating
0 Buy
4 Hold
0 Sell
Hold
Current: 6.040
Low
7.00
Averages
8.25
High
10.00
Current: 6.040
Low
7.00
Averages
8.25
High
10.00
About BHC
Bausch Health Companies Inc. is a global, diversified pharmaceutical company. The Salix segment includes sales in the U.S. of GI products. The International segment includes sales of Bausch + Lomb products and Solta Medical aesthetic medical devices, outside the U.S. and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical products and OTC products. The Solta Medical segment includes global sales of Solta Medical aesthetic medical devices. The Diversified segment includes sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, dermatology products, generic pharmaceutical products and dentistry products. The Bausch + Lomb segment includes global sales of Bausch + Lomb Vision Care, Surgical and Pharmaceuticals products. Its drug candidate, Larsucosterol binds to and inhibits the activity of DNA methyltransferases, epigenetic enzymes that are elevated and associated with hypermethylation found in AH patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Bausch Health Launches New Laser Device in Canada
- Market Expansion: Bausch Health and Solta Medical have launched the Clear + Brilliant®Touch laser in Canada, marking a significant step in expanding their market share amid growing demand for non-invasive skin rejuvenation treatments.
- Technological Innovation: Approved by Health Canada in May 2025, the device features dual-wavelength laser technology that offers customizable treatment options suitable for various skin types and ages, enhancing treatment flexibility and effectiveness.
- Clinical Support: The Clear + Brilliant® laser platform is backed by over 15 clinical studies, effectively improving skin appearance and addressing early signs of aging, further solidifying Solta Medical's leadership in the global aesthetics market.
- Strategic Importance: This product launch not only strengthens Bausch Health's competitiveness in the aesthetics sector but also reflects the company's recognition of Canada's growth potential, aiming to meet the increasing consumer demand through innovative technology.
See More
ARESTIN® Celebrates 25th Anniversary Milestone
- Clinical Milestone: ARESTIN® (minocycline HCl) microspheres, the only FDA-approved locally applied antibiotic, has been clinically used for 25 years, aiding over one billion people in managing periodontal disease, highlighting its significance in oral health management.
- Innovative Treatment Method: Utilizing microsphere technology, ARESTIN delivers antibiotics directly into the periodontal pocket, gradually releasing the medication, which significantly enhances treatment efficacy and fills a gap in periodontal disease management, promoting non-surgical treatment advancements.
- Market Expansion Strategy: OraPharma's recent commercial expansion into Canada and Puerto Rico aims to improve treatment options for patients in these regions, reflecting the company's commitment to addressing unmet needs and further solidifying its market position in dentistry.
- Future Development Vision: Bausch Health executives emphasize that while celebrating past achievements, the focus will remain on innovation and deeper collaboration with the dental community to drive ongoing improvements in periodontal health.
See More
Bausch Health Reports Strong Q4 2025 Earnings with Strategic Acquisition
- Consistent Growth: Bausch Health achieved its 11th consecutive quarter of revenue and adjusted EBITDA growth, with full-year results exceeding guidance on all key metrics, demonstrating robust market performance and ongoing operational efficiencies.
- Strategic Acquisition: The company acquired Shibo, a full-service aesthetics distribution platform in China, on December 1, 2025, enhancing its direct commercial presence in one of the largest global aesthetics markets, which is expected to further boost market share and customer base.
- Financial Performance: Fourth-quarter revenue reached $1.391 billion, a 9% year-over-year increase, while adjusted EBITDA was $773 million, up 13%, reflecting strong performance in core products like Xifaxan and Thermage.
- Future Outlook: Management anticipates 2026 revenues between $5.25 billion and $5.4 billion, with adjusted EBITDA expected between $2.875 billion and $2.95 billion, indicating steady growth despite challenges from patent expirations and regulatory changes.
See More
Bausch Health (BHC) Q4 2025 Earnings Transcript
See More
Bausch Health Q4 2025 Earnings Highlights
- Sustained Growth: Bausch Health reported Q4 2025 revenue of $1.391 billion, a 9% year-over-year increase, reflecting strong performance across markets and further solidifying its position in the global pharmaceutical industry.
- Adjusted EBITDA Growth: Adjusted EBITDA reached $773 million, up 9% from the previous year, exceeding expectations and demonstrating effective management in cost control and growth investments, enhancing future financial flexibility.
- Strategic Acquisition: The acquisition of Shibo, a full-service aesthetics distribution platform in China in December 2025, strengthens direct commercial presence in the largest global aesthetics market, expected to drive future revenue growth and market share expansion.
- Debt Structure Optimization: Through a $1.7 billion debt exchange, Bausch Health significantly improved its debt maturity profile, enhancing financial stability and providing greater flexibility for future business development.
See More
Bausch Health Reports Q4 2025 Earnings Miss
- Earnings Miss: Bausch Health's Q4 2025 financial results revealed a GAAP EPS of -$0.30, significantly below the expected $0.42, causing a ~4% drop in after-hours trading.
- Revenue Growth vs. Rising Expenses: The company reported revenue of approximately $2.8 billion, a 9.5% year-over-year increase that beat the consensus of $2.71 billion; however, a 16% YoY increase in expenses to ~$2.3 billion negatively impacted profitability.
- Positive Revenue Guidance: Bausch provided a 2026 revenue guidance of $10.625 billion to $10.875 billion, exceeding the consensus estimate of $10.52 billion, indicating confidence in future growth prospects.
- Improved Cash Position: By the end of 2025, Bausch's cash, cash equivalents, and restricted cash totaled $1.325 billion, up from $1.2 billion on December 31, 2024, reflecting better liquidity management.
See More
Bausch Health Launches New Laser Device in Canada
- Market Expansion: Bausch Health and Solta Medical have launched the Clear + Brilliant®Touch laser in Canada, marking a significant step in expanding their market share amid growing demand for non-invasive skin rejuvenation treatments.
- Technological Innovation: Approved by Health Canada in May 2025, the device features dual-wavelength laser technology that offers customizable treatment options suitable for various skin types and ages, enhancing treatment flexibility and effectiveness.
- Clinical Support: The Clear + Brilliant® laser platform is backed by over 15 clinical studies, effectively improving skin appearance and addressing early signs of aging, further solidifying Solta Medical's leadership in the global aesthetics market.
- Strategic Importance: This product launch not only strengthens Bausch Health's competitiveness in the aesthetics sector but also reflects the company's recognition of Canada's growth potential, aiming to meet the increasing consumer demand through innovative technology.
See More
ARESTIN® Celebrates 25th Anniversary Milestone
- Clinical Milestone: ARESTIN® (minocycline HCl) microspheres, the only FDA-approved locally applied antibiotic, has been clinically used for 25 years, aiding over one billion people in managing periodontal disease, highlighting its significance in oral health management.
- Innovative Treatment Method: Utilizing microsphere technology, ARESTIN delivers antibiotics directly into the periodontal pocket, gradually releasing the medication, which significantly enhances treatment efficacy and fills a gap in periodontal disease management, promoting non-surgical treatment advancements.
- Market Expansion Strategy: OraPharma's recent commercial expansion into Canada and Puerto Rico aims to improve treatment options for patients in these regions, reflecting the company's commitment to addressing unmet needs and further solidifying its market position in dentistry.
- Future Development Vision: Bausch Health executives emphasize that while celebrating past achievements, the focus will remain on innovation and deeper collaboration with the dental community to drive ongoing improvements in periodontal health.
See More
Bausch Health Reports Strong Q4 2025 Earnings with Strategic Acquisition
- Consistent Growth: Bausch Health achieved its 11th consecutive quarter of revenue and adjusted EBITDA growth, with full-year results exceeding guidance on all key metrics, demonstrating robust market performance and ongoing operational efficiencies.
- Strategic Acquisition: The company acquired Shibo, a full-service aesthetics distribution platform in China, on December 1, 2025, enhancing its direct commercial presence in one of the largest global aesthetics markets, which is expected to further boost market share and customer base.
- Financial Performance: Fourth-quarter revenue reached $1.391 billion, a 9% year-over-year increase, while adjusted EBITDA was $773 million, up 13%, reflecting strong performance in core products like Xifaxan and Thermage.
- Future Outlook: Management anticipates 2026 revenues between $5.25 billion and $5.4 billion, with adjusted EBITDA expected between $2.875 billion and $2.95 billion, indicating steady growth despite challenges from patent expirations and regulatory changes.
See More
Bausch Health (BHC) Q4 2025 Earnings Transcript
See More
Bausch Health Q4 2025 Earnings Highlights
- Sustained Growth: Bausch Health reported Q4 2025 revenue of $1.391 billion, a 9% year-over-year increase, reflecting strong performance across markets and further solidifying its position in the global pharmaceutical industry.
- Adjusted EBITDA Growth: Adjusted EBITDA reached $773 million, up 9% from the previous year, exceeding expectations and demonstrating effective management in cost control and growth investments, enhancing future financial flexibility.
- Strategic Acquisition: The acquisition of Shibo, a full-service aesthetics distribution platform in China in December 2025, strengthens direct commercial presence in the largest global aesthetics market, expected to drive future revenue growth and market share expansion.
- Debt Structure Optimization: Through a $1.7 billion debt exchange, Bausch Health significantly improved its debt maturity profile, enhancing financial stability and providing greater flexibility for future business development.
See More
Bausch Health Reports Q4 2025 Earnings Miss
- Earnings Miss: Bausch Health's Q4 2025 financial results revealed a GAAP EPS of -$0.30, significantly below the expected $0.42, causing a ~4% drop in after-hours trading.
- Revenue Growth vs. Rising Expenses: The company reported revenue of approximately $2.8 billion, a 9.5% year-over-year increase that beat the consensus of $2.71 billion; however, a 16% YoY increase in expenses to ~$2.3 billion negatively impacted profitability.
- Positive Revenue Guidance: Bausch provided a 2026 revenue guidance of $10.625 billion to $10.875 billion, exceeding the consensus estimate of $10.52 billion, indicating confidence in future growth prospects.
- Improved Cash Position: By the end of 2025, Bausch's cash, cash equivalents, and restricted cash totaled $1.325 billion, up from $1.2 billion on December 31, 2024, reflecting better liquidity management.
See More
